The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Designing Libraries with CNS Activity
Abstract
Library design is an important and difficult task. In this paper we describe one possible solution to designing a CNS-active library. CNS-actives and -inactives were selected from the CMC and the MDDR databases based on whether they were described as having some kind of CNS activity in the databases. This classification scheme results in over 15 000 actives and over 50 000 inactives. Each molecule is described by 7 1D descriptors (molecular weight, number of donors, number of acceptors, etc.) and 166 2D descriptors (presence/absence of functional groups such as NH(2)). A neural network trained using Bayesian methods can correctly predict about 75% of the actives and 65% of the inactives using the 7 1D descriptors. The performance improves to a prediction accuracy on the active set of 83% and 79% on the inactives on adding the 2D descriptors. On a database with 275 compounds where the CNS activity is known (from the literature) for each compound, we achieve 92% and 71% accuracy on the actives and inactives, respectively. The models we construct can therefore be used as a "filter" to examine any set of proposed molecules in a chemical library. As an example of the utility of our method, we describe the generation of a small library of potentially CNS-active molecules that would be amenable to combinatorial chemistry. This was done by building and analyzing a large database of a million compounds constructed from frameworks and side chains frequently found in drug molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Properties of Known Drugs. 1. Molecular Frameworks
Bemis, G. W., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9602928 · Cited by 2,482
Self-citationConcepts and applications of molecular similarity
Johnson, M. A., & Maggiora, G. M. (1990) · Wiley eBooks · Cited by 1,301
Walters, W. P., Stahl, M. T., & Murcko, M. A. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01163-x · Cited by 991
Self-citationLevin, V. A. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00180a022 · Cited by 813
Comprehensive Medicinal Chemistry
(1991) · Quantitative Structure-Activity Relationships · doi:10.1002/qsar.19910100410 · Cited by 745
Brown, R. D., & Martin, Y. C. (1996) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci9501047 · Cited by 625
van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
Young, R. C., Mitchell, R. C., Brown, T. H., Ganellin, C. R., Griffiths, R., Jones, M., Rana, K. K., Saunders, D., & Smith, I. R. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00398a028 · Cited by 521
Can We Learn To Distinguish between “Drug-like” and “Nondrug-like” Molecules?
Ajay, Walters, W. P., & Murcko, M. A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970666c · Cited by 484
Self-citationCNS Drug Design Based on Principles of Blood‐Brain Barrier Transport
Pardridge, W. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051781.x · Cited by 460
Cited by
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
The Many Roles of Computation in Drug Discovery
Jorgensen, W. L. (2004) · Science · doi:10.1126/science.1096361 · Cited by 1,554
Medicinal chemical properties of successful central nervous system drugs
Pajouhesh, H., & Lenz, G. R. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.541 · Cited by 1,535
Simple Selection Criteria for Drug-like Chemical Matter
Muegge, I., Heald, S. L., & Brittelli, D. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015507e · Cited by 1,315
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Integration of virtual and high-throughput screening
Bajorath, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd941 · Cited by 930
Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., & Polli, J. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039255 · Cited by 614
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599
Blood-brain barrier drug targeting: the future of brain drug development.
Pardridge, W. M. (2003) · Molecular Interventions · doi:10.1124/mi.3.2.90 · Cited by 570
The application of in silico drug-likeness predictions in pharmaceutical research
Tian, S., Wang, J., Li, Y., Li, D., Xu, L., & Hou, T. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.009 · Cited by 498
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
Walters, W. P., & Murcko, M. A. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00003-0 · Cited by 439
Self-citationVolSurf: a new tool for the pharmacokinetic optimization of lead compounds
Cruciani, G., Pastor, M., & Guba, W. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00162-7 · Cited by 419
Selection criteria for drug‐like compounds
Muegge, I. (2003) · Medicinal Research Reviews · doi:10.1002/med.10041 · Cited by 412
Drug and Gene Delivery to the Brain
Pardridge, W. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01054-1 · Cited by 405
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Self-citationThe p KaDistribution of Drugs: Application to Drug Discovery
Manallack, D. T. (2007) · Perspectives in Medicinal Chemistry · doi:10.1177/1177391x0700100003 · Cited by 354
Recent advances in computer-aided drug design
Song, C. M., Lim, S. J., & Tong, J. C. (2009) · Briefings in Bioinformatics · doi:10.1093/bib/bbp023 · Cited by 344
A Bayesian Approach to in Silico Blood-Brain Barrier Penetration Modeling
Martins, I. F., Teixeira, A. L., Pinheiro, L., & Falcao, A. O. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300124c · Cited by 331
Carpenter, T. S., Kirshner, D. A., Lau, E. Y., Wong, S. E., Nilmeier, J. P., & Lightstone, F. C. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.06.024 · Cited by 306
Benchmarking the Reliability of QikProp. Correlation between Experimental and Predicted Values
Ioakimidis, L., Thoukydidis, L., Mirza, A., Naeem, S., & Reynisson, J. (2008) · QSAR & Combinatorial Science · doi:10.1002/qsar.200730051 · Cited by 294
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
Agarwal, S., Sane, R., Oberoi, R., Ohlfest, J. R., & Elmquist, W. F. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001888 · Cited by 292
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Properties of Known Drugs. 2. Side Chains
Bemis, G. W., & Murcko, M. A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9903996 · Cited by 271
Self-citationA Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Sun, J., Ou, W., Han, D., Paganini-Hill, A., Fisher, M. J., & Sumbria, R. K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0268860 · Cited by 47
Metadata
- Authors
- Ajay, Bemis, G. W., & Murcko, M. A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-11-10
- Volume
- 42
- Issue
- 24
- Pages
- 4942-4951
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2085645854
- Cited by
- 316
- References
- 18
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.